Table 1.
Enteric-Coated Nanoparticle Formulations for Non-Colorectal Cancer
| No | Polymer | Active Ingredient | Application | Ref |
|---|---|---|---|---|
| 1. | Propylene glycol alginate sodium sulfate | – | Potential enteric delivery system | 90 |
| 2. | Copper-substituted mesoporous silica | 16-Hydroxy-cleroda-3,13-dien-16,15-olide (HCD) | Controlled anti-glioma drug delivery | 91 |
| 3. | Starch and chitosan | Withania coagulans extract | Enteric extract delivery system | 92 |
| 4. | Polylactic acid (PLA), polyvinyl alcohol, poloxamer 188 | β-galactosidase | Protection on enzymatic degradation | 93 |
| 5. | PLGA, lipid, PEG | Insulin | Oral insulin delivery system | 94 |
| 6. | Polyacrylic resin II (PRII) and solid lipid (polyvinyl alcohol and octadecanoic acid) | Enrofloxacin (ENR) | Enteric delivery and light protector system | 51 |
| 7. | Deoxycholic acid-conjugated chitosan | Insulin | Oral insulin delivery system | 95 |
| 8. | Hydroxypropyl methylcellulose and Eudragit® L100 | Darunavir | Enteric antivirus delivery system | 96 |
| 9. | (methoxy-polyethylene glycol)-b-poly(D,L-lactide-co-glycolide)-b-poly(L-lysine) | Peptide Val-Leu-Pro-Val-Pro-Arg | Enteric peptide delivery system | 97 |
| 10. | Hyaluronic acid, chitosan, and Eudragit® L-100 | Insulin | Oral insulin delivery system | 98 |
| 11. | Chitosan and Eudragit® L-100 | Bovine serum albumin (BSA) | Oral protein vaccine delivery system | 99 |
| 12. | Deoxycholic acid conjugated PEGylated polyhydroxybutyrate | Insulin | Oral insulin delivery system | 100 |
| 13. | Hyaluronic acid (HA) | Insulin | Oral insulin delivery system | 101 |
| 14. | Guar gum and Eudragit® L30D | Amphotericin B | Antileishmanial drug delivery system | 102 |
| 15. | Compritol 888 ATO, cetyl palmitate, stearic acid, Dynasan® 114, Dynasan® 116, Dynasan® 118, Gelucire® 50/13, Softisan® 154, lauric acid, glyceril monostearate, glyceril trioleat, Labrafil® M-2151 CS, Labrafac® WL 1349, corn oil, sesame oil, sthyl oleat, oleic acid, Eudragit® S100 | Budesonide | Inflammatory Bowel Disease | 103 |
| 16. | Gelatin, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), monophosphoryl lipid A, glycerol tripalmitate, and cholesterol | HBsAg | Oral vaccine delivery system | 104 |
| 17. | Eudragit® S-100 and Eudragit® L-100 | Sulfasalazine | Oral-specific delivery | 105 |
| 18. | Glyceryl monooleate and Eudragit® L100-55 | Pravastatin sodium (PVS) | Duodenum-triggered delivery | 106 |
| 19. | Eudragit® L100-55 and polyvinyl alcohol | Nifedipine | Oral pH-sensitive delivery | 107 |
| 20. | N-(2-hydroxy)-propyl-3-trimethylammonium chloride modified chitosan (HTCC) and sodium tripolyphosphate (TPP) | Insulin | Oral insulin delivery system | 108 |
| 21. | Mesoporous silica | Safranin O | Colonic targeted delivery system | 109 |
| 22. | Monomethoxyl poly(ethylene glycol)-b-poly(L-lactide-co-glycolide) | Growth factor | Enteric protein delivery system | 110 |
| 23. | Hydroxypropyl methylcellulose phthalate (HPMCP) | Omeprazole | Enteric drug delivery system | 111 |
| 24. | Hydroxypropyl methylcellulose phthalate (HP55), poly(lactic-co-glycolic acid) (PLGA), and Eurdragit® RS | Insulin | Oral insulin delivery system | 112 |
| 25. | Polyacrylic acid | Papain | Small intestine targeted delivery system | 113 |
| 26. | Polyethylene imine | Insulin | Oral insulin delivery system | 114 |
| 27. | Mesoporous silica and polyacrylic acid | Metoprolol tartrate | Enteric delivery and sustained release system | 115 |
| 28. | Eudragit® RS100 and poly(lactic-co-glycolic acid) (PLGA) | Lansoprazole | Enteric delivery and sustained release system | 116 |
| 29. | Eudragit® L100 | Darunavir | Enteric antivirus delivery system | 117 |
| 30. | Methacrylic acid-methyl methacrylate and chitosan | Recombinant human keratinocyte growth factor (rHuKGF) | Enteric protein delivery system | 118 |
| 31. | Phospholipon® 90H, Arlacel® 1689, Crodamol® CP-PA-(SG), and Eudragit® S100 | Lipo-endomorphin-1 | Enteric peptide delivery system | 119 |
| 32. | Compritol 888 ATO (COMP) and Poloxamer 188 (P-188) | Carvedilol | Lymphatic absorption | 120 |
| 33. | poly(g-glutamic acid) and chitosan | Exendin-4 | Enteric peptide delivery system | 121 |
| 34. | Poly(methacrylic acid)-polysorbate 80-grafted-starch terpolymer and ethylcellulose | Diltiazem | Enteric delivery and controlled release system | 122 |
| 35. | Pluronic | Efavirenz | Microfold cells (M-cells) targeted delivery system | 123 |
| 36. | Poly(D,L-lactide-co-glycolide) and Eudragit S100 | Eluxadoline | Enteric delivery and sustained release system | 124 |
| 37. | Alginate and chitosan | Goat anti-mouse IgG peroxidise conjugate | Oral vaccine delivery system | 125 |
| 38. | Hydroxypropyl methylcellulose phthalate (HP55) | Insulin | Oral insulin delivery system | 126 |
| 39. | Diethylene triamine pentaacetic acid and poly(γ-glutamic acid) | Insulin | Oral insulin delivery system | 127 |
| 40. | Folate-chitosan | 5-fluourouacil (5-FU) and leucovorin (LV) | Multiple drug and targeted delivery system | 128 |
| 41. | Poly(lactic-co-glycolic acid) | Docetaxel | Lymphatic absorption | 129 |
| 42. | Chitosan and Eudragit L-100 | Insulin | Oral insulin delivery system | 130 |
| 43. | Acrylic acid and methacrylic | Rifampicin | Sustained release and mucoadhesive delivery | 131 |
| 44. | Poloxamer 188, polyvinyl alcohol, and polyacryl resin II | Tilmicosin | Prevent gastrointestinal degradation | 132 |